FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017310071> ?p ?o ?g. }

• W2017310071 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCGlioblastomas are a highly aggressive and detrimental brain tumor, comprising 50% of all human gliomas. Glioblastomas have a median survival of less than two years after diagnosis because it has a high capacity for proliferation and is extremely chemoresistant. A common molecular event that characterizes glioblastoma is constitutive activation of the RAS-RAF-MAPK signaling pathway. Activating mutation of BRAF (BRAF-V600E) has been reported in a subset of these tumors. We recently developed UI-152 as the new oncogenic BRAF targeting drug. In biochemical assays, UI-152 inhibited BRAF-V600E at very low nanomolar concentrations and showed a 10-fold higher potency against BRAF-V600E than another well-known oncogenic BRAF inhibitor, PLX4032/4720. In the present study, we evaluated the individual IC50 values of UI-152 from the cell growth inhibitory effects of the six malignant glioma cell lines with different BRAF mutational status. KG-1-C, NMC-G1, and DBTRG-05MG cell lines are heterozygous for BRAF-V600E; A-172, T98G, and U-87MG cell lines are homozygous for wild-type (WT) BRAF. The IC50 values of UI-152 were determined using crystal violet assays. UI-152 displayed the greatest level of selectivity for BRAF-mutant cells, inhibiting their proliferation more potently than that of cells expressing BRAF-WT. The IC50 of UI-152 in B-Raf mutant cells was less than 0.2 μM, whereas the IC50 of cells expressing BRAF-WT were not reached even at 20 μM UI-152. Corresponding immunoblot results showed that UI-152 completely abolished MEK-ERK phosphorylation in DBTRG-05MG cells harboring BRAF-V600E. However, in U-87MG cells expressing BRAF-WT, UI-152 caused the paradoxical activation of the MAPK pathway. UI-152 induced the phosphorylation of MEK/ERK at 5 μM but caused a return to control levels at 10 μM in U-87MG cells. These results indicate that the genetic profile test of glioma is necessary prior to BRAF-targeted therapy to patients. Taken together, our data suggest that UI-152 may be an effective BRAF inhibitor and contribute to a potential therapeutic strategy for brain tumor patients with BRAF mutations.Citation Format: Michael Lee, Jun-Ho Ahn, Soon Kil Ahn, Yong W. Lee. Differential sensitivity of BRAF mutant glioma cell lines to the new oncogenic BRAF kinase inhibitor UI-152. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 940. doi:10.1158/1538-7445.AM2013-940" @default.
• W2017310071 created "2016-06-24" @default.
• W2017310071 creator A5001606591 @default.
• W2017310071 creator A5004975261 @default.
• W2017310071 creator A5026925984 @default.
• W2017310071 creator A5069667659 @default.
• W2017310071 date "2013-04-15" @default.
• W2017310071 modified "2023-09-26" @default.
• W2017310071 title "Abstract 940: Differential sensitivity of BRAF mutant glioma cell lines to the new oncogenic BRAF kinase inhibitor UI-152." @default.
• W2017310071 doi "https://doi.org/10.1158/1538-7445.am2013-940" @default.
• W2017310071 hasPublicationYear "2013" @default.
• W2017310071 type Work @default.
• W2017310071 sameAs 2017310071 @default.
• W2017310071 citedByCount "0" @default.
• W2017310071 crossrefType "proceedings-article" @default.
• W2017310071 hasAuthorship W2017310071A5001606591 @default.
• W2017310071 hasAuthorship W2017310071A5004975261 @default.
• W2017310071 hasAuthorship W2017310071A5026925984 @default.
• W2017310071 hasAuthorship W2017310071A5069667659 @default.
• W2017310071 hasConcept C104317684 @default.
• W2017310071 hasConcept C121608353 @default.
• W2017310071 hasConcept C126322002 @default.
• W2017310071 hasConcept C143065580 @default.
• W2017310071 hasConcept C1491633281 @default.
• W2017310071 hasConcept C153911025 @default.
• W2017310071 hasConcept C184235292 @default.
• W2017310071 hasConcept C2776470698 @default.
• W2017310071 hasConcept C2777752497 @default.
• W2017310071 hasConcept C2778227246 @default.
• W2017310071 hasConcept C2779707156 @default.
• W2017310071 hasConcept C2781249067 @default.
• W2017310071 hasConcept C501734568 @default.
• W2017310071 hasConcept C502942594 @default.
• W2017310071 hasConcept C54355233 @default.
• W2017310071 hasConcept C57074206 @default.
• W2017310071 hasConcept C62112901 @default.
• W2017310071 hasConcept C71924100 @default.
• W2017310071 hasConcept C81885089 @default.
• W2017310071 hasConcept C86803240 @default.
• W2017310071 hasConceptScore W2017310071C104317684 @default.
• W2017310071 hasConceptScore W2017310071C121608353 @default.
• W2017310071 hasConceptScore W2017310071C126322002 @default.
• W2017310071 hasConceptScore W2017310071C143065580 @default.
• W2017310071 hasConceptScore W2017310071C1491633281 @default.
• W2017310071 hasConceptScore W2017310071C153911025 @default.
• W2017310071 hasConceptScore W2017310071C184235292 @default.
• W2017310071 hasConceptScore W2017310071C2776470698 @default.
• W2017310071 hasConceptScore W2017310071C2777752497 @default.
• W2017310071 hasConceptScore W2017310071C2778227246 @default.
• W2017310071 hasConceptScore W2017310071C2779707156 @default.
• W2017310071 hasConceptScore W2017310071C2781249067 @default.
• W2017310071 hasConceptScore W2017310071C501734568 @default.
• W2017310071 hasConceptScore W2017310071C502942594 @default.
• W2017310071 hasConceptScore W2017310071C54355233 @default.
• W2017310071 hasConceptScore W2017310071C57074206 @default.
• W2017310071 hasConceptScore W2017310071C62112901 @default.
• W2017310071 hasConceptScore W2017310071C71924100 @default.
• W2017310071 hasConceptScore W2017310071C81885089 @default.
• W2017310071 hasConceptScore W2017310071C86803240 @default.
• W2017310071 hasLocation W20173100711 @default.
• W2017310071 hasOpenAccess W2017310071 @default.
• W2017310071 hasPrimaryLocation W20173100711 @default.
• W2017310071 hasRelatedWork W1417458945 @default.
• W2017310071 hasRelatedWork W1546835108 @default.
• W2017310071 hasRelatedWork W1983915589 @default.
• W2017310071 hasRelatedWork W2019410232 @default.
• W2017310071 hasRelatedWork W2022538402 @default.
• W2017310071 hasRelatedWork W2055028127 @default.
• W2017310071 hasRelatedWork W2171238773 @default.
• W2017310071 hasRelatedWork W2227227984 @default.
• W2017310071 hasRelatedWork W2234345059 @default.
• W2017310071 hasRelatedWork W2320942517 @default.
• W2017310071 hasRelatedWork W2322808366 @default.
• W2017310071 hasRelatedWork W2497243288 @default.
• W2017310071 hasRelatedWork W2508665420 @default.
• W2017310071 hasRelatedWork W2510700839 @default.
• W2017310071 hasRelatedWork W2743651870 @default.
• W2017310071 hasRelatedWork W2791484514 @default.
• W2017310071 hasRelatedWork W2791811230 @default.
• W2017310071 hasRelatedWork W2901818168 @default.
• W2017310071 hasRelatedWork W3012050408 @default.
• W2017310071 hasRelatedWork W3178771046 @default.
• W2017310071 isParatext "false" @default.
• W2017310071 isRetracted "false" @default.
• W2017310071 magId "2017310071" @default.
• W2017310071 workType "article" @default.